Browsing Tag
Enhertu
16 posts
Avacta (AIM: AVCT): First patient dosed in FOCUS-01 with three data catalysts lined up across 2026
Avacta (AIM: AVCT) dosed the first FOCUS-01 patient in March 2026. Three catalysts follow: AACR April 21, AVA6000 H1 update, AVA6103 late H2 data. Full retail investor roadmap inside.
AstraZeneca FY2025 results analysis: How oncology scale, China exposure, and pipeline depth are reshaping long-term earnings power
AstraZeneca’s FY2025 results reveal what’s driving growth, where risks are building, and how pipeline depth could shape earnings beyond 2030. Read the full analysis.
AstraZeneca, Daiichi Sankyo score tenth BTD for Enhertu in early HER2 disease
AstraZeneca and Daiichi Sankyo’s Enhertu earns FDA breakthrough tag in early breast cancer. Find out what this means for HER2 treatment strategy in 2025.
AstraZeneca and Daiichi Sankyo win FDA approval for Enhertu combo as new standard in HER2 mBC
Enhertu plus pertuzumab gets FDA approval for first-line HER2-positive mBC, setting a new standard in metastatic breast cancer care. Read what changes now.
EirGenix signs global licensing deal with Sandoz for second HER2 biosimilar EG1206A
EirGenix signs a USD 152M global deal with Sandoz for its Perjeta biosimilar EG1206A after FDA/EMA nod. Find out what this means for the HER2 drug race.
AstraZeneca’s $13.6bn Q1 2025 sales surge as cancer drugs and AI deals set stage for $80bn goal
Explore how AstraZeneca’s strong Q1 2025 results, new drug approvals, and AI-powered R&D are reshaping its global growth story.
EU approves Enhertu as first HER2-targeted therapy for HR-positive, HER2-low metastatic breast cancer
Discover how Enhertu’s EU approval is transforming care for HR-positive, HER2-low and HER2-ultralow breast cancer, and what it means for AstraZeneca’s future.
AstraZeneca reports strong FY 2024 results with robust revenue growth driven by oncology and biopharmaceuticals
AstraZeneca’s financial performance for fiscal year 2024 reflects impressive growth, with the pharmaceutical giant reporting a 21% surge…
ENHERTU gains FDA approval for HER2 low or ultralow metastatic breast cancer treatment
Daiichi Sankyo and AstraZeneca’s ENHERTU (fam-trastuzumab deruxtecan-nxki) has secured approval from the U.S. Food and Drug Administration (FDA)…
ENHERTU receives EU approval for advanced non-small cell lung cancer
The European Union (EU) has given its nod to ENHERTU (trastuzumab deruxtecan) for the treatment of adult patients…